Gotham Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $64M | Buy |
82,846
+2,575
| +3% | +$1.97M | 0.2% | 42 |
|
|
2025
Q4 | $62M | Sell |
80,271
-3,959
| -5% | -$2.69M | 0.23% | 34 |
|
|
2025
Q3 | $47.4M | Buy |
84,230
+57,225
| +212% | +$32.4M | 0.21% | 39 |
|
|
2025
Q2 | $14.2M | Sell |
27,005
-5,042
| -16% | -$2.81M | 0.08% | 348 |
|
|
2025
Q1 | $20.3M | Buy |
32,047
+20,624
| +181% | +$14.2M | 0.17% | 105 |
|
|
2024
Q4 | $8.14M | Buy |
11,423
+5,796
| +103% | +$4.86M | 0.08% | 369 |
|
|
2024
Q3 | $5.92M | Sell |
5,627
-73
| -1% | -$81.2K | 0.06% | 439 |
|
|
2024
Q2 | $5.99M | Buy |
5,700
+2,345
| +70% | +$2.27M | 0.08% | 369 |
|
|
2024
Q1 | $3.23M | Buy |
3,355
+206
| +7% | +$196K | 0.05% | 501 |
|
|
2023
Q4 | $2.77M | Sell |
3,149
-98
| -3% | -$80.7K | 0.05% | 484 |
|
|
2023
Q3 | $2.67M | Sell |
3,247
-6,606
| -67% | -$5.19M | 0.06% | 470 |
|
|
2023
Q2 | $7.08M | Buy |
9,853
+5,897
| +149% | +$4.55M | 0.15% | 139 |
|
|
2023
Q1 | $3.25M | Sell |
3,956
-228
| -5% | -$172K | 0.08% | 335 |
|
|
2022
Q4 | $3.02M | Sell |
4,184
-1,386
| -25% | -$1.02M | 0.09% | 295 |
|
|
2022
Q3 | $3.84M | Sell |
5,570
-8,660
| -61% | -$5.45M | 0.11% | 215 |
|
|
2022
Q2 | $8.41M | Sell |
14,230
-870
| -6% | -$566K | 0.27% | 69 |
|
|
2022
Q1 | $10.5M | Sell |
15,100
-8,564
| -36% | -$5.42M | 0.33% | 50 |
|
|
2021
Q4 | $14.9M | Buy |
23,664
+18,261
| +338% | +$11.2M | 0.48% | 22 |
|
|
2021
Q3 | $3.27M | Buy |
5,403
+1,871
| +53% | +$1.16M | 0.13% | 204 |
|
|
2021
Q2 | $1.97M | Buy |
3,532
+267
| +8% | +$135K | 0.08% | 315 |
|
|
2021
Q1 | $1.54M | Sell |
3,265
-778
| -19% | -$379K | 0.07% | 347 |
|
|
2020
Q4 | $1.95M | Sell |
4,043
-8,786
| -68% | -$4.74M | 0.06% | 351 |
|
|
2020
Q3 | $7.18M | Buy |
12,829
+8,581
| +202% | +$5.2M | 0.23% | 127 |
|
|
2020
Q2 | $2.65M | Sell |
4,248
-668
| -14% | -$379K | 0.08% | 315 |
|
|
2020
Q1 | $2.4M | Buy |
4,916
+3,184
| +184% | +$1.31M | 0.07% | 371 |
|
|
2019
Q4 | $650K | Sell |
1,732
-3,681
| -68% | -$1.24M | 0.01% | 725 |
|
|
2019
Q3 | $1.5M | Sell |
5,413
-28,527
| -84% | -$8.44M | 0.03% | 503 |
|
|
2019
Q2 | $10.6M | Buy |
33,940
+18,900
| +126% | +$6.29M | 0.17% | 167 |
|
|
2019
Q1 | $6.18M | Buy |
15,040
+3,954
| +36% | +$1.63M | 0.09% | 298 |
|
|
2018
Q4 | $4.14M | Sell |
11,086
-910
| -8% | -$333K | 0.06% | 366 |
|
|
2018
Q3 | $4.85M | Sell |
11,996
-10,026
| -46% | -$3.82M | 0.07% | 352 |
|
|
2018
Q2 | $7.6M | Buy |
22,022
+17,972
| +444% | +$5.62M | 0.11% | 263 |
|
|
2018
Q1 | $1.4M | Sell |
4,050
-109
| -3% | -$37.9K | 0.02% | 559 |
|
|
2017
Q4 | $1.56M | Sell |
4,159
-30,016
| -88% | -$12.2M | 0.02% | 525 |
|
|
2017
Q3 | $15.3M | Buy |
+34,175
| New | +$16.3M | 0.22% | 138 |
|
|
2017
Q1 | – | Sell |
-12,096
| Closed | -$4.44M | – | 1087 |
|
|
2016
Q4 | $4.44M | Sell |
12,096
-12,649
| -51% | -$4.81M | 0.06% | 402 |
|
|
2016
Q3 | $9.95M | Sell |
24,745
-5,406
| -18% | -$2.17M | 0.13% | 241 |
|
|
2016
Q2 | $10.5M | Buy |
30,151
+27,626
| +1,094% | +$10.6M | 0.13% | 267 |
|
|
2016
Q1 | $910K | Sell |
2,525
-1,632
| -39% | -$672K | 0.01% | 668 |
|
|
2015
Q4 | $2.26M | Buy |
+4,157
| New | +$2.25M | 0.02% | 513 |
|
|
2014
Q4 | – | Sell |
-1,410
| Closed | -$508K | – | 1029 |
|
|
2014
Q3 | $508K | Buy |
1,410
+529
| +60% | +$177K | 0.01% | 762 |
|
|
2014
Q2 | $249K | Buy |
+881
| New | +$261K | ﹤0.01% | 921 |
|
|
2013
Q4 | – | Sell |
-3,285
| Closed | -$1.03M | – | 1021 |
|
|
2013
Q3 | $1.03M | Buy |
+3,285
| New | +$864K | 0.03% | 574 |
|
Other funds holding REGN
VCM
N
Gotham Asset Management's REGN Position: Q1 2026 in Review
Gotham Asset Management increased its Regeneron Pharmaceuticals (REGN) stake by 3.2% in Q1 2026, buying an estimated $1.97M and bringing the position to 82,846 shares worth $64M. The position accounts for 0.2% of the portfolio, ranked #42.
Gotham Asset Management first reported a position in REGN in Q3 2013 and has held it in 43 quarters since. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Gotham Asset Management held 82,846 shares of Regeneron Pharmaceuticals worth $64M as of Q1 2026.
- Gotham Asset Management bought 2,575 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $1.97M.
- Regeneron Pharmaceuticals made up 0.2% of Gotham Asset Management's portfolio in Q1 2026, its #42 holding.
- Gotham Asset Management first reported a position in Regeneron Pharmaceuticals in Q3 2013 and has held it in 43 quarters since.
- 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Gotham Asset Management's 13F filing for Q1 2026, filed 15 May 2026.